China Pharma Holdings, Inc.
CPHI
$0.3034
$0.01083.69%
| Weiss Ratings | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Very Weak | |||
| Beta / Standard Deviation | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.70 | |||
| Price History | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -2.53% | |||
| 30-Day Total Return | -8.79% | |||
| 60-Day Total Return | -28.76% | |||
| 90-Day Total Return | -40.95% | |||
| Year to Date Total Return | -43.84% | |||
| 1-Year Total Return | -78.67% | |||
| 2-Year Total Return | -97.68% | |||
| 3-Year Total Return | -99.22% | |||
| 5-Year Total Return | -98.12% | |||
| 52-Week High % Change | -87.90% | |||
| 52-Week Low % Change | 20.30% | |||
| Price | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.70 | |||
| 52-Week Low Price | $0.30 | |||
| 52-Week Low Price (Date) | Apr 18, 2024 | |||
| 52-Week High Price (Date) | May 01, 2023 | |||
| Valuation | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 4.71M | |||
| Enterprise Value | 7.92M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.06 | |||
| Earnings Per Share Growth | -72.00% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.33 | |||
| Price/Book (Q) | 0.45 | |||
| Enterprise Value/Revenue (TTM) | 1.15 | |||
| Price | $0.33 | |||
| Enterprise Value/EBITDA (TTM) | 4,466.93 | |||
| Enterprise Value/EBIT | -2.92 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 7.28M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 86 89 8668 11730 | |||
| Address | -- | |||
| Website | www.chinapharmaholdings.com | |||
| Country | China | |||
| Year Founded | -- | |||
| Profitability | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -39.24% | |||
| Profit Margin | -43.91% | |||
| Management Effectiveness | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -10.04% | |||
| Return on Equity | -- | |||
| Income Statement | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 7.01M | |||
| Total Revenue (TTM) | 7.01M | |||
| Revenue Per Share | $0.96 | |||
| Gross Profit (TTM) | -281.20K | |||
| EBITDA (TTM) | 1.80K | |||
| EBIT (TTM) | -2.75M | |||
| Net Income (TTM) | -3.08M | |||
| Net Income Avl. to Common (TTM) | -3.08M | |||
| Total Revenue Growth (Q YOY) | -26.41% | |||
| Earnings Growth (Q YOY) | 2.53% | |||
| EPS Diluted (TTM) | -1.06 | |||
| EPS Diluted Growth (Q YOY) | 82.77% | |||
| Balance Sheet | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.42M | |||
| Cash Per Share (Q) | $0.20 | |||
| Total Current Assets (Q) | 6.00M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 7.45M | |||
| Current Ratio (Q) | 0.879 | |||
| Book Value Per Share (Q) | $0.70 | |||
| Total Assets (Q) | 16.47M | |||
| Total Current Liabilities (Q) | 6.82M | |||
| Total Debt (Q) | 4.63M | |||
| Total Liabilities (Q) | 9.01M | |||
| Total Common Equity (Q) | 7.45M | |||
| Cash Flow | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -11.50K | |||
| Cash from Financing (TTM) | 73.10K | |||
| Net Change in Cash (TTM) | -606.00K | |||
| Levered Free Cash Flow (TTM) | -168.60K | |||
| Cash from Operations (TTM) | -699.60K | |||
